Personalized immunotherapy for the treatment of non‐Hodgkin's lymphoma: a promising approach

Publisher Website
Google Scholar
Abstract
The efficacy of immunotherapeutic strategies for the treatment of lymphoid malignancies has been demonstrated in recent years. In patients with B‐cell lymphomas, particularly indolent lymphoma, the use of passive immunotherapy, such as the anti‐CD20 monoclonal antibody rituximab, has made an impressive impact on patient outcome. Personalized immunotherapy, a method that triggers the immune system to mount a response against tumor cells, has shown promising results in early clinical trials in hematologic malignancies. This therapeutic modality appears safe, with the most common adverse events being transient, local reactions at the site of injection. Furthermore, personalized immunotherapy has the potential to generate immunologic memory, which could provide prolonged remission. Currently, 3 large phase III studies are evaluating the efficacy and safety of personalized immunotherapy in patients with follicular lymphoma [1–3]. It is hoped that the results of these studies will lead to the incorporation of this promising approach into the standard treatment of patients with lymphoma. Copyright © 2006 John Wiley & Sons, Ltd.